Virtual Seminar: Dissecting Toxicities of Immune Checkpoint Inhibitors
Douglas Johnson, M.D., MSCI
Associate Professor of Medicine
Clinical Director, Melanoma Program
Ingram Cancer Center
Vanderbilt University
Virtual Pioneers in Biomedical Research Seminar: Dissecting Toxicities of Immune Checkpoint Inhibitors
Nov. 19, 2021
11:00 a.m. to 12:00 p.m.
Archived video
About this Seminar
Anti-PD-1 therapy has dramatically altered cancer treatments, but many unanswered questions remain. First, the need for more accurate biomarkers to provide clues to the pathogenesis of response and resistance, and to more accurately assign patients to effective treatment remains a key unmet need. Tumor cell expression of MHC class II and tumor mutational burden are two potential markers of response. Second, patients treated with anti-PD-1, especially when used in combination, frequently experience severe immune-related toxicities. Identifying patients at risk, clinically phenotyping clinical events, and determine effective treatment strategies remain unmet needs. In this presentation, Dr. Johnson will discuss his lab's work in identifying anti-PD-1 biomarkers, particularly focusing on MHC-II and tumor mutational burden, and in characterizing anti-PD-1 toxicities.
Additional Details
This is a free event hosted by the Fralin Biomedical Research Institute and co-sponsored by the institute's Cancer Research Group. The Pioneers in Biomedical Research Seminar Series, which runs annually from September to May, has featured leading biomedical researchers from throughout the country since the program began in 2012. The lectures are also open to all members of the Virginia Tech community including graduate students, undergraduates, faculty, and staff, as well as the public.
You May Also Be Interested In...
-
Home Item
Addictive Nicotine and Stress Induce Convergent Mechanisms That Increase Alcohol Self‐administration , homeFeb. 21, 2025, 11:00 a.m. | John Dani, Ph.D., Professor of Neurological Sciences, Chair, Department of Neuroscience, Scientific Director, UPENN, CNS Consortium, Perlman School of Medicine, University of Pennsylvania | Co-Sponsored by the Fralin Biomedical Research Institute Center for Human Neuroscience Research
-
Home Item
Exploring the Functional Role of Gene Variation in Nicotine and Alcohol Abuse , homeFeb. 21, 2025, 1 p.m. | Mariella De Biasi, Ph.D., Professor, Director, Program for Cholingeric Mechanisms in Addiction, Perlman School of Medicine, University of Pennsylvania | Co-Sponsored by the Fralin Biomedical Research Institute Center for Human Neuroscience Research
-
Home Item
The Relationship between Mitochondrial Function and Heart Failure , homeFeb. 28, 2025, 11:00 a.m. | Rong Tian, M.D., Ph.D., Professor, Department of Anesthesiology and Bioengineering, University of Washington | Co-Sponsored by the Fralin Biomedical Research Institute Center for Vascular and Heart Research
-
Home Item
Suicide by Firearm in the United States: A Collaborative Path for Prevention , homeMarch 6, 2025, 5:30 p.m. (Reception at 5 p.m.) | Marian Betz, M.D., M.P.H. Professor, Departments of Epidemiology and Emergency Medicine, Deputy Director, Injury & Violence Prevention Center, University of Colorado School of Public Health; Member, National Academy of Medicine | Maury Strauss Distinguished Public Lecture
-
Home Item
Thinking the Right Thoughts , homeMarch 7, 2025, 11:00 a.m. | Nathaniel Daw, Ph.D., Professor, Computational and Theoretical Neuroscience, Department of Psychology, Princeton University | Co-Sponsored by the Fralin Biomedical Research Institute Center for Human Neuroscience Research
-
Home Item
The Emergence of Network Activity Patterns - An Early Window to Autism Spectrum Disorder , homeMarch 14, 2025, 11:00 a.m. | Natalia De Marco Garcia, Ph.D., Associate Professor, Department of Neuroscience, The Brain and Mind Research Institute, Weill Cornell Medical College | Co-Sponsored by the Center for Neurobiology Research, Fralin Biomedical Research Institute